A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2015
At a glance
- Drugs MK 2206 (Primary) ; Selumetinib (Primary)
- Indications Colorectal cancer; Malignant melanoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 Planned end date changed from 1 Apr 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 30 Jan 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2014 to 1 Apr 2014.